Natera Oncology

Watch Brent's inspiring story and how Signatera testing helped him stay ahead in his fight against bladder cancer. As Bladder Cancer Awareness Month comes to a close, we are proud to share stories like Brent's today and all year long, to inspire and showcase the power of personalized cancer monitoring. 💪💛 #BladderCancerAwareness #Signatera #Natera #CancerSurvivor #SurvivorStrong #BladderCancerAwarenessMonth See the full story: https://ow.ly/BZyB50S1ZiJ

Skin cancer (also known as melanoma) is the MOST common cancer in the United States. You can take steps this summer to lower your and your family's risk for cancer. Save these tips for a more safe day in the sun. ☀️ #SkinCancerAwareness #SkinCancer #SunProtection #Melanoma

How do you determine which patients are likely to recur after cystectomy without adjuvant treatment? Support your patients this #BladderCancer awareness month and learn how Signatera can help identify MIBC patients who may benefit from adjuvant therapy after cystectomy. Click the PDF below for more details the outcomes of the study IMvigor010, the first randomized, phase III, global registrational study, in high-risk, muscle-invasive bladder cancer (MIBC). Did you know? Signatera can be run at any time point on the core biopsy or surgical resection and is covered by Medicare and a growing number of commercial payers for MIBC patients and any patient being treated with immunotherapy Learn more on our website: https://ow.ly/ReYO50RSSG1

[WEBINAR] Join us tomorrow for our webinar: Latest data on #ctDNA as a patient selection and early efficacy marker for #gynecologic cancers. Circulating tumor DNA (ctDNA), as measured by the Signatera assay, has emerged as a highly sensitive biomarker to identify patient populations who are at high risk of relapse and may benefit from additional treatment. Signatera™ is now covered by Medicare for patients with stage II-IV ovarian, fallopian tube, or primary peritoneal cancer in the adjuvant and surveillance settings, expanding access to testing. Our expert speakers will discuss the latest data from recent publications and SGO 2024 supporting the use of ctDNA in gynecologic cancer clinical practice and trials. This will be followed by a panel discussion on the future directions and implications for drug development and clinical trial design in this rapidly evolving space. https://ow.ly/RFhV50RYoCa

We are pleased to present new data at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 31 – June 4, 2024. Our presentations feature data across a variety of indications, including breast cancer, colorectal cancer, lung cancer, melanoma, esophageal cancer, and urothelial cancer, with one oral presentation and 12 poster presentations on #Signatera, our personalized and tumor-informed molecular residual disease test, as well as one poster with data on Empower, our test for hereditary cancer. Minetta Liu, MD, chief medical officer of oncology at Natera, said, “We look forward to sharing new data across cancer types, reflecting Natera’s deep clinical pipeline in MRD with results from randomized trials as well as real-world studies. This includes promising new findings from the CIRCULATE-Japan GALAXY study demonstrating the prognostic and predictive utility of Signatera and actionable biomarkers in colorectal cancer.” https://ow.ly/cv0R50RSpGq #Natera #ASCO24 #CancerResearch

Join us at #ASCO24, where we will be presenting data demonstrating the clinical utility and performance of Signatera Residual Disease (MRD) test for patients with various solid tumor types. Visit booth 13047 to meet our team and learn about our expanding body of data in solid tumor malignancies. See the full details: https://lnkd.in/eTB2eShh #Natera #MRD #CancerResearch

May is Bladder Cancer Awareness Month. While we we know early detection is key, we also feel strongly about the importance of managing recurrence for those affected by bladder cancer. Learn more about how #Signatera can help to detect early signs of bladder cancer recurrence ahead of traditional imaging, helping to identify patients who may benefit from additional treatment and support evaluating treatment response. https://ow.ly/8xeO50RytLB

We are pleased to announce the latest publication in JCO Precision Oncology reporting on the ability of our personalized and tumor-informed molecular residual disease (MRD) test, Signatera, to detect recurrence early in patients with early-stage breast cancer. The study evaluated a total of 1,136 prospectively collected and banked plasma samples from 156 early-stage breast cancer patients enrolled in the multi-site Exploratory Breast Lead Interval Study (EBLIS). “This expanded EBLIS study reinforces the importance of early recurrence detection with Signatera and the potential to improve care management for patients with breast cancer,” said Minetta Liu, MD, chief medical officer of oncology. “The findings also bolster the evidence for long-term monitoring of high-risk breast cancer patients, who often face late recurrences.” Read the full announcement here: https://ow.ly/4wKQ50Rw7OC #JCOPrecision #JCOPO #JCOPrecisionOncology #PrecisionOncology

Thank you Breast Cancer Resource Center (BCRC) for all you do to empower those affected by breast cancer. Learn more below. #CancerResources #BreastCancer

❄️ A little snow couldn't stop #TeamNatera from supporting Bladder Cancer Advocacy Network in Denver for their Walk to End Bladder Cancer. We're proud to sponsor this event and support their mission to give bladder cancer patients and caregivers the resources and support they need to cope with the disease. #Natera #BladderCancerAwareness #BladderCancer #EndBladderCancer